## Jesmin Shafiq

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3858851/publications.pdf

Version: 2024-02-01

567281 377865 1,700 34 15 34 citations h-index g-index papers 34 34 34 2291 docs citations times ranked citing authors all docs

#	Article	lF	Citations
1	Estimating the demand for radiotherapy from the evidence: A review of changes from 2003 to 2012. Radiotherapy and Oncology, 2014, 112, 140-144.	0.6	387
2	Role of radiotherapy in cancer control in low-income and middle-income countries. Lancet Oncology, The, 2006, 7, 584-595.	10.7	249
3	Do multidisciplinary team meetings make a difference in the management of lung cancer?. Cancer, 2011, 117, 5112-5120.	4.1	150
4	Use of chemotherapy at end of life in oncology patients. Annals of Oncology, 2009, 20, 1555-1559.	1.2	137
5	An international review of patient safety measures in radiotherapy practice. Radiotherapy and Oncology, 2009, 92, 15-21.	0.6	113
6	The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with Bone Metastases: The EORTC QLQ-BM22. European Journal of Cancer, 2009, 45, 1146-1152.	2.8	108
7	Management of skin toxicity during radiation therapy: A review of the evidence. Journal of Medical Imaging and Radiation Oncology, 2010, 54, 264-279.	1.8	97
8	The population benefit of evidence-based radiotherapy: 5-Year local control and overall survival benefits. Radiotherapy and Oncology, 2018, 126, 191-197.	0.6	71
9	Mechanisms of vasodilation induced by NKH477, a water-soluble forskolin derivative, in smooth muscle of the porcine coronary artery Circulation Research, 1992, 71, 70-81.	4.5	57
10	Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases. European Journal of Cancer, 2009, 45, 2510-2518.	2.8	50
11	The Benefits of Providing External Beam Radiotherapy in Low- and Middle-income Countries. Clinical Oncology, 2017, 29, 72-83.	1.4	34
12	A Population-based Model of Local Control and Survival Benefit of Radiotherapy for Lung Cancer. Clinical Oncology, 2016, 28, 627-638.	1.4	28
13	An evidence-based estimation of local control and survival benefit of radiotherapy for breast cancer. Radiotherapy and Oncology, 2007, 84, 11-17.	0.6	26
14	The population benefit of radiotherapy for cervical cancer: Local control and survival estimates for optimally utilized radiotherapy and chemoradiation. Radiotherapy and Oncology, 2015, 114, 389-394.	0.6	26
15	Comparison of Magnetic Resonance Imaging and Computed Tomography for Breast Target Volume Delineation in Prone and Supine Positions. International Journal of Radiation Oncology Biology Physics, 2016, 96, 905-912.	0.8	18
16	Impact of radiotherapy underutilisation measured by survival shortfall, years of potential life lost and disability-adjusted life years lost in New South Wales, Australia. Radiotherapy and Oncology, 2018, 129, 191-195.	0.6	17
17	Radiotherapy underutilisation and its impact on local control and survival in New South Wales, Australia. Radiotherapy and Oncology, 2019, 141, 41-47.	0.6	16
18	A comparison of surgical and radiotherapy breast cancer therapy utilization in Canada (British) Tj ETQq0 0 0 rgE Breast, 2012, 21, 570-577.	BT /Overloc 2.2	k 10 Tf 50 67 14

Breast, 2012, 21, 570-577.

#	Article	IF	CITATIONS
19	Establishing treatment benchmarks for mammographyâ€screened breast cancer population based on a review of evidenceâ€based clinical guidelines. Cancer, 2008, 112, 1912-1922.	4.1	11
20	Estimating the cost of radiotherapy for 5-year local control and overall survival benefit. Radiotherapy and Oncology, 2019, 136, 154-160.	0.6	11
21	Estimation of the optimal utilisation rates of radical prostatectomy, external beam radiotherapy and brachytherapy in the treatment of prostate cancer by a review of clinical practice guidelines. Radiotherapy and Oncology, 2016, 118, 118-121.	0.6	10
22	Variation in the use of radiotherapy fractionation for breast cancer: Survival outcome and cost implications. Radiotherapy and Oncology, 2020, 152, 70-77.	0.6	10
23	A comparison of systemic breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal―therapy. Breast, 2012, 21, 562-569.	2.2	8
24	Patterns of use of palliative radiotherapy fractionation for bone metastases and 30-day mortality. Radiotherapy and Oncology, 2021, 154, 299-305.	0.6	8
25	Dosimetric implications of the addition of 18 fluorodeoxyglucoseâ€positron emission tomography in CTâ€based radiotherapy planning for nonâ€smallâ€cell lung cancer. Journal of Medical Imaging and Radiation Oncology, 2010, 54, 152-160.	1.8	6
26	Estimating the Population Benefit of Radiotherapy: Using Demand Models to Estimate Achievable Cancer Outcomes. Clinical Oncology, 2015, 27, 99-106.	1.4	6
27	Patterns of palliative radiotherapy fractionation for brain metastases patients in New South Wales, Australia. Radiotherapy and Oncology, 2021, 156, 174-180.	0.6	6
28	Surgical and radiotherapy patterns of care in the management of breast cancer in NSW and ACT Australia. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 442-454.	1.8	6
29	Radiotherapy patterns of care for stage I and II nonâ€small cell lung cancer in Sydney, Australia. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 131-141.	1.8	5
30	Translation of oncology multidisciplinary team meeting (MDM) recommendations into clinical practice. BMC Health Services Research, 2021, 21, 461.	2.2	5
31	Radiotherapy service need in the Pacific Island countries. Asia-Pacific Journal of Clinical Oncology, 2021, 17, e217-e225.	1.1	4
32	Predicting 2-year survival in stage I-III non-small cell lung cancer: the development and validation of a scoring system from an Australian cohort. Radiation Oncology, 2022, 17, 74.	2.7	3
33	Trends in the use of shortâ€course radiation therapy for rectal cancer in New South Wales, Australia. Journal of Medical Imaging and Radiation Oncology, 2021, , .	1.8	2
34	Radiotherapy might not be the answer in Africa – Authors' reply. Lancet Oncology, The, 2006, 7, 705-706.	10.7	1